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ABSTRACT
HIV-1 protease (PR), reverse transcriptase (RT), and integrase (IN) variability presents a challenge to laboratories performing
genotypic resistance testing. This challenge will grow with increased sequencing of samples enriched for proviral DNA such as
dried blood spots and increased use of next-generation sequencing (NGS) to detect low-abundance HIV-1 variants. We analyzed
PR and RT sequences from>100,000 individuals and IN sequences from>10,000 individuals to characterize variation at each
amino acid position, identify mutations indicating APOBEC-mediated G-to-A editing, and identify mutations resulting from
selective drug pressure. Forty-seven percent of PR, 37% of RT, and 34% of IN positions had one or more amino acid variants
with a prevalence of >1%. Seventy percent of PR, 60% of RT, and 60% of IN positions had one or more variants with a preva-
lence of >0.1%. Overall 201 PR, 636 RT, and 346 IN variants had a prevalence of >0.1%. The median intersubtype prevalence
ratios were 2.9-, 2.1-, and 1.9-fold for these PR, RT, and IN variants, respectively. Only 5.0% of PR, 3.7% of RT, and 2.0% of IN
variants had a median intersubtype prevalence ratio of >10-fold. Variants at lower prevalences were more likely to differ bio-
chemically and to be part of an electrophoretic mixture compared to high-prevalence variants. There were 209 mutations indica-
tive of APOBEC-mediated G-to-A editing and 326 mutations nonpolymorphic treatment selected. Identification of viruses with a
high number of APOBEC-associated mutations will facilitate the quality control of dried blood spot sequencing. Identifying se-
quences with a high proportion of rare mutations will facilitate the quality control of NGS.
IMPORTANCE
Most antiretroviral drugs target three HIV-1 proteins: PR, RT, and IN. These proteins are highly variable: many different amino
acids can be present at the same position in viruses from different individuals. Some of the amino acid variants cause drug resis-
tance and occur mainly in individuals receiving antiretroviral drugs. Some variants result from a human cellular defense mecha-
nism called APOBEC-mediated hypermutation. Many variants result from naturally occurring mutation. Some variants may
represent technical artifacts. We studied PR and RT sequences from>100,000 individuals and IN sequences from>10,000 indi-
viduals to quantify variation at each amino acid position in these three HIV-1 proteins. We performed analyses to determine
which amino acid variants resulted from antiretroviral drug selection pressure, APOBEC-mediated editing, and naturally occur-
ring variation. Our results provide information essential to clinical, research, and public health laboratories performing geno-
typic resistance testing by sequencing HIV-1 PR, RT, and IN.
As HIV-1 has spread among humans, it has developed an ex-traordinary amount of genetic diversity (1). This diversity
arises from HIV-1’s high mutation rate and predilection for re-
combination (2, 3). Amino acid variants accumulate within an
individual as a result of various selective pressures and HIV-1’s
genetic robustness or tolerance for a large number of different
amino acid variants (4, 5). The large number of protease (PR),
reverse transcriptase (RT), and integrase (IN) amino acid variants
has implications for antiretroviral (ARV) therapy and presents a
challenge to laboratories performing genotypic resistance testing.
The challenge of HIV-1 genotypic resistance test interpretation
is increasing with the adoption of dried blood spot sequencing in
low- and middle-income countries and the expansion of next-
generation sequencing (NGS) in upper-income countries. Dried
blood spot samples contain proviral DNA, which is more likely to
contain APOBEC-mediated G-to-A hypermutation, an ancient
host defense mechanism responsible for lethal mutagenesis (6).
NGS technologies are intrinsically more error prone than dide-
oxynucleotide terminator Sanger sequencing and are at risk of
yielding reports of low-abundance variants that result from PCR
error (7, 8).
We analyzed PR and RT direct PCR Sanger sequences from
more than 100,000 individuals and IN direct PCR Sanger se-
quences from more than 10,000 individuals to characterize the
amino acid variation at each amino acid position in these genes.
We also analyzed sequences from individuals with known ARV
treatment histories to identify those mutations resulting from se-
lective drug pressure. Knowledge of the observed variation and
selection pressure on the molecular targets of HIV therapy can be
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useful to clinical, research, and public health laboratories per-
forming genotypic resistance testing.
MATERIALS AND METHODS
Sequences.HIV-1 group M protease (PR), reverse transcriptase (RT), and
integrase (IN) sequences determined by direct PCR dideoxynucleotide
sequencing were retrieved from the Stanford HIV Drug Resistance Data-
base (HIVDB) on 1 April 2015 (9). These sequences included 119,000 PR,
128,000 RT, and 13,000 IN sequences from 132,000 individuals in 143
countries. Eighty-five percent of the sequences are in GenBank; 15% were
submitted directly to HIVDB. The subtype of each sequence was deter-
mined using the REGA HIV-1 Subtyping Tool version 3 (10). The five
most common subtypes were B (61%), C (12%), CRF01_AE (8%),
CRF02_AG (5%), and A (5%). Clonal sequences were excluded to mini-
mize the likelihood of detecting random virus polymerization errors
or—in the case of molecular cloning—PCR errors (11).
Ninety-four percent of sequences were obtained from plasma. Plasma
sequences were used to analyze overall amino acid variation and ARV
selection pressure. Six percent of sequences were obtained from periph-
eral blood mononuclear cell (PBMC) proviral DNA. PBMC sequences
were pooled with the plasma virus sequences in our analysis of APOBEC-
associated mutations because proviral DNA is enriched for APOBEC-
edited virus genomes (12, 13).
APOBEC-associatedmutations.To identify amino acid changes con-
sistent with APOBEC editing, we first identified all highly conserved GG
or GA dinucleotide positions in PR, RT, and IN sequences from plasma
samples. Conserved dinucleotides were defined as those present in 98% of
pooled samples and in each of the five most common subtypes. We then
identified sequences containing mutations that resulted from canonical
APOBEC3G (GG¡AG) and 3F (GA¡AA) G-to-A changes at these
highly conserved dinucleotide positions. Sequences with these candidate
APOBEC-associated mutations were then examined for stop codons—a
specific indicator of APOBEC-mediated editing of tryptophan codons
(TGG)—and for the number of additional candidate APOBEC-associated
mutations.
To identify the number of APOBEC-associated mutations to use as a
cutoff for classifying a sequence as likely to have undergone G-to-A hy-
permutation, we assumed a mixture of two Poisson distributions with
different ’s defined as the average number of APOBEC-associated mu-
tations in a sequence: (i) a distribution with a lower  reflecting sequences
lacking APOBEC-associated mutations or containing sparse APOBEC-
associated mutations resulting from random HIV mutations and (ii) an-
other distribution with a higher  reflecting sequences with abundant
APOBEC-associated mutations resulting from host APOBEC-3F and
APOBEC-3G enzymatic activity. We then developed an R package,
LocFDRPois, to estimate the local false discovery rate for each number of
APOBEC-associated mutations at which a sequence with that number of
APOBEC-associated mutations did not arise from APOBEC editing (http:
//cran.r-project.org/web/packages/LocFDRPois/).
Theoretically APOBEC-edited genomes should not be found in
plasma at a detectable level by Sanger sequencing because these viruses
usually cannot complete a virus replication cycle (14). However, plasma
can occasionally be contaminated by proviral DNA, which would be ex-
tracted and amplified by most HIV sequencing protocols. Therefore, in
our subsequent analyses, we excluded all sequences likely to be hypermu-
tated.
Amino acid variants. To characterize variability at each position in
PR, RT, and IN, we determined the proportion of each amino acid at each
position in all viruses and in each of the five most common HIV-1 sub-
types. Each amino acid variant was also characterized by its biochemical
relatedness to the consensus amino acid at that position using the
BLOSUM62 and BLOSUM80 amino acid similarity matrices. The
BLOSUM62 and BLOSUM80 matrices are based on the likelihood that
two amino acids can replace one another in genomes that share up to 62%
and 80% amino acid similarity, respectively, regardless of the organisms
from which they were obtained. Thus, they represent the extent of bio-
chemical similarity between amino acids, which is independent of histor-
ical evolution and local sequence context. For notational purposes, amino
acid variants were defined as differences from the consensus subtype B
amino acid sequence because this is a commonly used reference and be-
cause it was nearly always the same as the consensus of all pooled se-
quences.
We also determined the proportion of times that each amino acid
variant occurred as part of an electrophoretic mixture in which two peaks
were present on the sequence electropherogram resulting in one of the
following ambiguous nucleotide calls: R (combination of A and G), Y
(combination of C and T), M (combination of A and C), W (combination
of A and T), K (combination of G and T), and S (combination of C and G)
(15). Amino acids that always occurred as part of an electrophoretic mix-
ture were excluded.
Nonpolymorphic TSMs. To identify nonpolymorphic treatment-se-
lected mutations (TSMs), we examined the treatment history of the indi-
viduals from whom each sequenced virus was obtained. For each drug
class—PR inhibitor (PI), nucleoside RT inhibitor (NRTI), nonnucleoside
RT inhibitor (NNRTI), and IN strand transfer inhibitor (INSTI)—se-
quences were characterized as being either from an ARV class-naive indi-
vidual who received no drugs belonging to the class or an ARV class-
experienced individual who received at least one drug from that class.
Sequences from individuals of unknown or uncertain treatment history
were excluded from this analysis. In sequences from patients with multi-
ple virus isolates, mutations occurring in more than one isolate were
counted just once.
We then examined each amino acid variant for its association with
ARV selection pressure. The proportion of each variant in ARV-experi-
enced individuals was compared to its proportion in ARV-naive individ-
uals using a chi-square test with Yates’ correction. The Holm’s method
was then used to control the family-wise error rate for multiple-hypoth-
esis testing at an adjusted P value of0.01 (16). To exclude TSMs under
minimal drug selection pressure, we included only those TSMs that were
five times more frequent in ARV-experienced than in ARV-naive individ-
uals. To identify the TSMs that are most specific for ARV selection across
subtypes, we identified those TSMs that were nonpolymorphic in the
absence of selective drug pressure, defined as occurring at a frequency
below 1.0% in ARV-naive individuals infected with viruses belonging to
each of the five most common subtypes.
Transmitted drug resistance (TDR) will cause many nonpolymorphic
TSMs to appear in virus sequences from untreated individuals. This will
cause the proportion of these mutations in ARV-naive individuals to be
higher than what would be expected in ARV-naive individuals whose
viruses had not experienced selective drug pressure. This in turn will re-
duce the ratio of the prevalence of these mutations in ARV-experienced
individuals divided by their inflated prevalence in ARV-naive individuals.
Therefore, we restricted our analysis of ARV-naive sequences to those
lacking any of the 93 surveillance drug resistance mutations (SDRMs) that
have become established markers of TDR (17). For IN for which the
SDRM list is not available, we used major INSTI resistance mutations
defined in Stanford HIVDB: T66I/A/K, E92Q, F121Y, G140S/A/C,
Y143C/R/H, S147G, Q148H/K/R, and N155H/S.
Among RT inhibitor (RTI)-experienced individuals, 75% received
NRTIs in combination with an NNRTI, 22% received NRTIs without an
NNRTI, and 3% received an NNRTI without an NRTI. The frequent use
of NRTIs in combination with an NNRTI makes it difficult to determine
for some mutations whether they are selected by NRTIs or NNRTIs.
Therefore, we first determined whether RT mutations were treatment
selected by comparing the proportions of mutations in sequences from
RTI-naive and RTI-experienced individuals. We then determined
whether the selection appeared to be primarily associated with NRTIs
versus NNRTIs using a previously described approach (18). Those muta-
tions that did not demonstrate a strong significant association with just
one class were classified as (i) NRTI associated if their positions are known
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to be associated with NRTI resistance, (ii) NNRTI associated if their po-
sitions are known to be associated with NNRTI resistance, or (iii) undif-
ferentiated RTI associated if their positions were not previously associated
with NRTI or NNRTI resistance.
Synonymous and nonsynonymous mutation rates. To determine
whether the overall nucleotide mutation rate at a codon influenced the
likelihood of developing amino acid variants, we estimated the synony-
mous and nonsynonymous rates at each codon in PR, RT, and IN for the
five most common subtypes. For each subtype, we used FastML (19) to
determine the most probable ancestral codon and then compared the
codon of each sequence to this codon to estimate the number of synony-
mous changes/number of potential synonymous changes (dS) and the
number of nonsynonymous changes/number of potential nonsynony-
mous changes (dN). Additionally, we examined each consensus amino
acid and TSM to determine the minimum number of nucleotide differ-
ences between their respective codons.
RESULTS
Signature mutations indicating APOBEC-mediated editing. Of
297 PR nucleic acids, 24 GG and GA dinucleotides at 22 amino
acid positions were conserved in more than 98% of sequences in
each of the most common five subtypes. Canonical APOBEC-
mediated changes at these positions—GG¡AG, GA¡AA, and
GG¡AA (if GG is followed by G)—would result in 58 different
amino acid mutations and two stop codons. Fifty of the 58 muta-
tions occurred in sequences from one or more plasma samples. Of
the 50 observed mutations, 32 were strongly associated with one
or more stop codon or with a canonical APOBEC-mediated mu-
tation at one or more of the active-site residues D25, G27, G49,
G51, and G52. Table S1 in the supplemental material lists the two
stop codons and the 32 PR mutations, which our analysis suggests
indicate APOBEC-mediated editing.
Of 1,680 RT nucleic acids, 128 GG and GA dinucleotides at 115
amino acid positions were conserved in 98% of sequences in
each of the five most common subtypes. Canonical APOBEC-
mediated changes at these positions would result in 241 different
amino acid mutations and 19 stop codons. One hundred eighty of
the 245 mutations occurred in sequences from one or more
plasma samples. Of the 180 observed mutations, 89 were signifi-
cantly associated with one or more of stop codons or with a ca-
nonical APOBEC-mediated mutation at one of the active-site res-
idues D110, D185, and D186. One of the 89 mutations, M230I, has
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FIG 1 Distribution of the number of HIV-1 protease (PR) amino acid variants by position stratified by prevalence:1% (A), 0.1% to 1% (B), 0.01% to 0.1%
(C), and0.01% (D). The total number of sequences analyzed at each position is shown on a log10 scale (E).
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recently been reported to cause resistance to the NNRTI rilpi-
virine (20). Table S1 in the supplemental material lists the 19 stop
codons and the 88 RT mutations that our analysis suggests indi-
cate APOBEC-mediated editing.
Of the 864 IN nucleic acids, 76 GG and GA dinucleotides at 65
amino acid positions were conserved in 98% of sequences in
each of the five most common subtypes. Canonical APOBEC-
mediated changes at these positions would result in 136 different
amino acid mutations and 7 stop codons. Eighty of the 136 muta-
tions occurred in sequences from one or more plasma samples. Of
these 80 mutations, 62 were significantly associated with one or
more stop codons or with a canonical APOBEC-mediated muta-
tion at one of the active-site residues D64, D116, and E152. One of
the 62 mutations, G118R, has recently been reported to reduce
susceptibility to multiple INSTIs (21, 22). Table S1 in the supple-
mental material lists the seven stop codons and the 61 IN mu-
tations that our analysis suggests indicate APOBEC-mediated
editing.
The local false discovery rate derived from the mixture model
described in Materials and Methods was used to classify sequences
as hypermutated or nonhypermutated based on the number of
signature APOBEC mutations within PR, RT, and IN (see Table S2
in the supplemental material). The presence of one signature mu-
tation predicted risks of hypermutation of 18%, 19%, and 16% for
PR, RT, and IN sequences, respectively. The presence of two sig-
nature mutations predicted risks of hypermutation of 86%, 79%,
and 76%, respectively. The presence of three signature mutations
predicted risks of hypermutation of 99.8%, 98.5%, and 97.8%,
respectively. Therefore, in our subsequent analyses, we excluded
112 PR, 225 RT, and 81 IN plasma sequences containing two or
more signature APOBEC mutations.
Amino acid variation. Overall, we analyzed 110,357 PR se-
quences obtained from 101,154 individuals, 118,246 RT se-
quences from 108,681 individuals, and 11,838 IN sequences from
11,156 individuals. Most RT sequences did not encompass the 3=
RNase H coding region of RT. Therefore, for our analysis of RT
amino acid variability, we included just positions 1 to 400.
Of the 99 PR positions, 47 (47%) had one or more variants
occurring at a prevalence of1%, and 69 (70%) had one or more
variants occurring at a prevalence of0.1% (Fig. 1). Overall, there
were 201 variants occurring at a prevalence of0.1% at these 69
positions (Table 1).
Of the 400 RT positions, 147 (37%) had one or more variants
occurring at a prevalence of1%, and 240 (60%) had one or more
variants in 0.1% of sequences (Fig. 2). Overall, there were 636
variants occurring at a prevalence of0.1% at these 240 positions
(Table 1).
Of the 288 IN positions, 97 (34%) had one or more variants
occurring at a prevalence of1%, and 172 (60%) had one or more
variants in 0.1% of sequences (Fig. 3). Overall, there were 346
variants occurring at a prevalence of0.1% at these 172 positions
(Table 1).
Variability between subtypes.At each position, the number of
amino acid variants with a prevalence of 0.1% was highly cor-
related between subtypes: The median intersubtype correlation
coefficients for the number of variants with a prevalence above
0.1% were 0.85 (P  2E16), 0.84 (P  2E16), and 0.68 (P 
2E16) for PR, RT, and IN, respectively (Fig. 4, 5, and 6).
For amino acid variants with a prevalence of 0.1%, the me-
dian intersubtype ratio of the prevalence for PR variants was 2.9-
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fold (interquartile range [IQR], 1.2- to 4.7-fold); only 5.0% of PR
variants had a prevalence in one subtype that differed by10-fold
in another subtype (range, 10- to 28-fold). The median intersub-
type ratio of the prevalence for RT variants was 2.1-fold (IQR, 1.0-
to 3.5-fold); only 3.7% of RT variants had a prevalence in one
subtype that differed by10-fold in another subtype (range, 10-
to 39-fold). The median intersubtype ratio of the prevalence for
IN variants was 1.9-fold (IQR, 1.2- to 3.0-fold); only 2.0% of IN
variants had a prevalence in one subtype that differed by10-fold
in another subtype (range, 10- to 51-fold).
Chemical relatedness. There was a strong relationship be-
tween the prevalence of an amino acid variant and its biochemical
similarity to the consensus amino acid (Table 1). Each 10-fold
increase in a variant’s prevalence was significantly correlated with
the change in BLOSUM62 similarity score: the slopes of a fitted
line for each gene were 0.71 (r 0.47; P 2E16), 0.67 (r 0.41;
P 2E16), and 0.68 (r 0.36; P 2E16) for PR, RT, and IN,
respectively. Similar results were obtained using the BLOSUM80
scoring matrix: the slopes of a fitted line for each gene were 0.81
(r 0.47; P 2E16), 0.77 (r 0.41; P 2E16), and 0.74 (r
0.35; P 2E16) for PR, RT, and IN, respectively.
Mixture analysis. There was a strong inverse relationship be-
tween a variant’s prevalence and the proportion of times that it
occurred as part of an electrophoretic mixture. Each 10-fold in-
crease in a variant’s prevalence was inversely correlated with the
change in the proportion of times that it occurred as part of an
electrophoretic mixture: the slopes of a fitted line for each gene
were3.6 (r 0.14; P 2E06),5.9 (r 0.32; P 2E16),
and7.6 (r 0.43; P 2E16) for PR, RT, and IN, respectively.
For example, the very rare variants with a prevalence of 0.01%
were present as a part of mixture in 54% to 60% of their occur-
rences, depending on the gene. In contrast, the most common
variants were present as a part of mixture in 7% to 9% of their
occurrences, depending on the gene (Table 1).
Very rare amino acid variants. The very rare variants occur-
ring at a prevalence of0.01% were evenly distributed through-
out PR, RT, and IN (coefficients of variation [CV], 29% for PR,
43% for RT, and 66% for IN) across positions whether they were
highly conserved or were variable at higher-mutation-prevalence
strata. In contrast, amino acid variants with higher prevalence had
a higher coefficient of variation than variants with lower preva-
lence: 1% (CV, 155% for PR, 179% for RT, and 170% for IN),
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FIG 2 Distribution of the number of HIV-1 reverse transcriptase (RT) amino acid variants by position stratified by prevalence:1% (A), 0.1% to 1% (B), 0.01%
to 0.1% (C), and0.01% (D). The total number of sequences analyzed at each position is shown on a log10 scale (E).
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0.1% to 1% (CV, 130% for PR, 147% for RT, and 139% for IN),
and 0.01% to 0.1% (CV, 73% for PR, 68% for RT, and 76% for IN)
(Fig. 1 to 3).
Table S3 in the supplemental material shows that 3.5% of
PR, 10.3% of RT, and 6.5% of IN sequences had 1 very rare
amino acid variant and 0.5% of PR, 2.2% of RT, and 0.9% of IN
sequences had 2 very rare amino acid variants. The steep
reduction in the proportion of sequences with increasing num-
bers of very rare amino acid variants followed a Poisson distri-
bution.
Nonpolymorphic TSMs. (i) PR. To identify nonpolymorphic
PI-selected mutations, we analyzed the proportions of all PR mu-
tations in sequences from 61,593 PI-naive individuals and 15,420
PI-experienced individuals. Within PR, 144 mutations at 57 posi-
tions were significantly more common in PI-experienced than
PI-naive patients after adjustment for multiple-hypothesis testing
by controlling the family-wise error rate (i.e., adjusted P) at0.01
(chi-square test; unadjusted P 8.8 106). Of these 144 muta-
tions, 111 at 41 positions were nonpolymorphic and occurred
more than five times more frequently in PI-experienced than PI-
naive individuals. Table 2 lists each of the 111 nonpolymorphic
TSMs by their position and frequency in ARV-experienced indi-
viduals.
Of the 88 PI nonpolymorphic TSMs that were previously
reported by us (18), two mutations, I13M and T74K, were no
longer found 5-fold more often in treated compared with un-
treated individuals. One mutation, Q58E, had a prevalence of
1.1% in subtype D viruses from untreated individuals. The 85
mutations in boldface were previously reported by us as non-
polymorphic TSMs, whereas the remaining 26 mutations are
newly identified. Ninety-two percent of the sequences contain-
ing a novel nonpolymorphic TSM had one or more PI-associ-
ated SDRMs.
(ii) RT. To identify nonpolymorphic RTI-selected mutations,
we analyzed the proportions of all RT mutations in sequences
from 52,040 RTI-naive and 28,806 RTI-experienced individuals.
Among the sequences from RTI-naive individuals, 22,810 encom-
passed RT positions 1 to 300, 4,790 encompassed RT positions 1 to
400, and 2,440 encompassed positions 1 to 560. Among the se-
quences from RTI-experienced individuals, 14,163 encompassed
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positions 1 to 300, 5,727 encompassed positions 1 to 400, and 437
encompassed positions 1 to 560.
Within RT, 245 mutations at 116 positions were significantly
more common in RTI-experienced than RTI-naive individuals
after adjustment for multiple-hypothesis testing by controlling
the family-wise error rate (i.e., adjusted P) at 0.01 (chi-square
test; unadjusted P 3.6  106). Of these 245 mutations, 185
mutations at 82 positions were nonpolymorphic and occurred
more than five times more frequently in RTI-experienced than
RTI-naive individuals. Table 3 lists each of the 95 nonpolymor-
phic NRTI-selected mutations. Table 4 lists each of the 64 non-
polymorphic NNRTI-selected mutations. Table 5 lists 26 non-
polymorphic RTI-selected mutations that could not be attributed
to either NRTI or NNRTI selection pressure alone and that oc-
curred at positions not previously associated with NRTI or
NNRTI selection pressure.
Of the 122 RTI nonpolymorphic TSMs that were previously
reported by us (18), two mutations, P236L and D237E, were no
longer found to be 5-fold more common in treated compared with
untreated individuals. One mutation, K43Q, was found to have a
prevalence of 2.0% in CRF01_AE viruses from ARV-naive indi-
viduals, and another mutation, L228H, was found to have a prev-
alence of 1.2% in subtype F viruses from ARV-naive individuals.
In Tables 3, 4, and 5, the 118 mutations shown in boldface were
previously reported by us to be nonpolymorphic TSMs, whereas
the remaining 63 are newly identified. Ninety-eight percent of the
sequences containing a novel nonpolymorphic TSM in RTI-expe-
rienced individuals had one or more RTI-associated SDRMs.
(iii) IN. To identify nonpolymorphic INSTI-selected muta-
tions, we analyzed the proportions of all IN mutations in se-
quences from 6,630 INSTI-naive and 1,020 INSTI-experienced
individuals. Within IN, 45 mutations at 28 positions were signif-
icantly more common in INSTI-experienced than INSTI-naive
individuals after adjustment for multiple-hypothesis testing by
controlling the family-wise error rate (i.e., adjusted P) at 0.01
(chi-square test; unadjusted P 1.3  105). Of these 45 muta-
tions, 44 occurred more than five times more frequently in INSTI-
experienced than INSTI-naive individuals. Of these 44 TSMs, 30
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at 15 positions were nonpolymorphic in INSTI-naive patients.
Table 6 shows those 30 nonpolymorphic TSMs. Of these 30 non-
polymorphic TSMs, 23 in boldface are established previously re-
ported DRMs (23), and the remaining 7 were new: V79I, E92A,
E138T, P142T, Q148N, N155D, and D253Y. Eighty-one percent
of the sequences containing a novel nonpolymorphic TSM had
one or more established INSTI-associated DRMs.
Synonymous and nonsynonymous mutation rates. Among
the 99 PR positions, dN was higher than dS at a median of 18
positions in the five most common subtypes. dN was higher than
dS in all five subtypes at positions 12, 13, 15, and 37. Among the
400 RT positions studied for amino acid variation, dN was higher
than dS at a median of 37 positions in the five most common
subtypes. dNwas higher than dS in all five subtypes at positions 35,
135, 178, 200, 202, 272, and 369. Among the 288 IN positions, dN
was higher than dS at a median of 28 positions in the five most
common subtypes. dN was higher than dS in all five subtypes at
positions 124 and 218.
Among the PR TSMs, the minimum numbers of nucleotide
differences between the TSM and the consensus amino acid vari-
ant were 1 for 67.6% and 2 for 32.4% (i.e., these were 2-bp muta-
tions). Among the RT TSMs, the minimum numbers of nucleo-
tide differences were 1 for 68.4%, 2 for 31.1%, and 3 for 0.6%.
Among the IN TSMs, the minimum numbers of nucleotide dif-
ferences were 1 for 86.7% and 2 for 13.3%.
DISCUSSION
Within an individual, HIV-1 variation arises from repeated cycles
of virus polymerization errors, recombination, APOBEC-medi-
ated RNA editing, and selective drug and immune pressure (24,
25). Although HIV-1 has a high mutation rate, only those variants
without significantly impaired fitness will rise to levels detectable
by standard direct PCR Sanger sequencing. In contrast, it is ex-
pected that many virus polymerization errors will result in nonvi-
able variants or variants that may not compete successfully with
more-fit virus variants (26). The consistent presence of certain
mutations by Sanger sequencing attests to their fitness at least
under some conditions and genetic contexts.
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An extensive amount of data are available for characterizing
HIV-1 PR, RT, and IN variability because these genes are fre-
quently sequenced for clinical, research, and epidemiological pur-
poses. We analyzed PR and RT sequences from more than 100,000
individuals and IN sequences from more than 10,000 individuals
and identified 1,183 amino acid variants in PR, RT, and IN that
were present in 0.1% of sequences. We also analyzed several
subsets of these sequences from individuals with known ARV
treatment histories and identified 326 nonpolymorphic PR, RT,
and IN TSMs.
Overall PR, RT, and IN variability. Forty-seven percent of PR,
37% of RT, and 34% of IN positions had one or more amino acid
variants with a prevalence of1%. Seventy percent of PR, 60% of
RT, and 60% of IN positions had one or more amino acid variants
with a prevalence of 0.1%. Although amino acid variants oc-
curred in different proportions in different subtypes, the preva-
lence of a variant in one subtype rarely differed by more than
10-fold compared with the prevalence of that variant in a different
subtype (2.0% of IN variants, 3.7% of RT variants, and 5.0% of PR
variants).
In each gene, the more rare the amino acid variant, the more
likely it was present as part of an electrophoretic mixture or dif-
fered biochemically from the consensus amino acid. Variants that
occur frequently as part of electrophoretic mixtures are likely to
have reduced replication fitness, explaining their inability to rep-
licate sufficiently to become dominant within an infected individ-
ual’s circulating virus population (27, 28). Although the presence
of two electrophoretic peaks at a position is usually a reliable in-
dicator that two nucleotides are present in that virus population, a
small secondary peak can also result from PCR error and sequenc-
ing artifact (29, 30).
Very rare variants had the lowest biochemical similarity to the
consensus amino acid at each position and often occurred as part
of an electrophoretic mixture. Additionally, these variants were
evenly distributed across all positions in PR, RT, and IN— occur-
ring in similar numbers at positions that were highly conserved or
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displayed variability at higher mutation thresholds. We propose
that it is useful to identify sequences that contain large numbers of
such rare variants because a high number of very rare amino acids
in a direct PCR dideoxynucleotide terminator Sanger sequence
could result from sequencing error or unrecognized frameshifts if
the rare amino acids are clustered. Additionally, the presence of a
high number of very rare variants in a next-generation deep-se-
quencing assay would be more consistent with PCR error than
quasispecies variation and would suggest that the threshold for
identification of low-abundance variants was set too low.
Treatment-selected mutations. We previously published an
analysis of nonpolymorphic TSMs in PR and the first 350 posi-
tions of RT using an earlier data set containing sequences from
approximately 25,000 individuals with known ARV treatment his-
tories (18). In this article, we extended our analysis of nonpoly-
morphic TSMs to IN and to the entire RT. In addition, the num-
bers of sequences from individuals with known treatment
histories in PR and the 5= part of RT were nearly three times higher
for PR and RT than those in our previous analysis.
We identified 111 nonpolymorphic PR TSMs: 26 new TSMs
and 85 of the 88 previously identified TSMs. The novel PR TSMs
are likely to be accessory drug resistance mutations because they
nearly always occurred in combination with established PI resis-
tance mutations.
We identified 185 nonpolymorphic RT TSMs: 67 new TSMs
and 118 of the 122 previously identified TSMs. The novel RT
TSMs were likely to be accessory drug resistance mutations be-
TABLE 2 PI nonpolymorphic treatment-selected mutations
Position Consa TSM(s)b
No. of
individuals
PI
treated
PI
naïve
10 L F9.5 R0.4 Y0.3 15,231 60,294
11 V L0.8 15,244 60,351
20 K T5.1 A0.1 15,278 61,114
22 A V0.9 15,292 61,145
23 L I1.2 15,295 61,252
24 L I5.9 F0.6 M0.2 15,282 61,263
30 D N6.3 15,302 61,316
32 V I5.1 15,302 61,323
33 L M0.1 15,302 61,317
34 E Q2.7 D0.3 V0.2 N0.1 R0.1 15,302 61,315
36 M A0.1 15,296 61,306
38 L W0.2 15,304 61,319
43 K T5.7 N0.4 I0.3 Q0.2 S0.1 P0.04 15,420 61,587
45 K Q0.3 I0.2 V0.1 15,421 61,587
46 M I22.7 L10.1 V0.5 15,412 61,594
47 I V4.9 A0.4 15,423 61,595
48 G V4.1 M0.5 A0.4 E0.2 Q0.1 S0.1 L0.1 T0.05 15,423 61,597
50 I V2.0 L0.5 15,423 61,597
51 G A0.3 15,422 61,592
53 F L6.0 Y0.4 I0.1 W0.1 15,423 61,598
54 I V25.5 L3.2 M2.8 A1.4 T0.9 S0.7 C0.04 15,422 61,594
55 K R7.6 N0.3 15,421 61,596
66 I F1.7 V1.2 L0.4 15,423 61,593
67 C F1.1 L0.1 15,418 61,577
71 A I3.2 L0.5 15,415 61,592
72 I L2.5 K0.7 15,417 61,574
73 G S8.7 T2.6 C1.2 A0.7 V0.2 D0.1 I0.1 N0.05 15,423 61,592
74 T P1.9 E0.1 15,421 61,591
76 L V3.8 15,419 61,585
79 P A0.9 N0.1 15,421 61,591
82 V A23.3 T3.2 F1.8 S1.4 C0.8 L0.3 M0.3 G0.2 15,414 61,582
83 N D0.8 S0.3 15,421 61,584
84 I V14.2 A0.2 C0.1 15,421 61,584
85 I V4.9 15,420 61,582
88 N D5.1 S1.5 G0.2 T0.1 15,418 61,543
89 L V4.2 T0.2 P0.1 15,412 61,533
90 L M32.0 I0.1 15,416 61,537
91 T S1.7 C0.1 15,417 61,536
92 Q R0.9 15,416 61,527
95 C F1.7 L0.2 V0.1 15,404 61,251
96 T S0.3 15,391 61,129
a Cons, consensus.
b Nonpolymorphic treatment-selected mutations (TSMs) in boldface were previously
reported as being associated with drug resistance (18).
TABLE 3 NRTI nonpolymorphic treatment-selected mutations
Position Consa TSM(s)b
No. of
individuals
RTI
treated
RTI
naive
40 E F0.6 28,619 51,040
41 M L28.5 28,761 51,192
43 K N1.7 D0.1 H0.1 28,768 51,944
44 E A1.5 28,769 51,957
64 K H0.6 N0.5 Y0.2 Q0.1 28,796 51,997
65 K R4.7 N0.1 E0.1 28,803 52,000
67 D N26.8 G2.5 E0.5 S0.3 H0.2 T0.2 A0.1 d0.1 28,792 51,999
68 S K0.1 28,804 52,003
69 T D6.1 i0.9 G0.2 d0.2 E0.2 Y0.1 28,789 52,005
70 K R18.1 E0.8 G0.4 T0.3 N0.3 Q0.3 S0.1 28,797 52,013
73 K M0.1 28,804 52,017
74 L V8.7 I4.2 28,799 52,021
75 V M3.3 I3.1 T1.4 A0.7 S0.3 28,798 52,034
77 F L1.7 28,805 52,035
115 Y F2.3 28,806 52,037
116 F Y2.0 28,807 52,044
117 S A0.2 28,802 52,037
151 Q M2.7 L0.2 K0.1 28,792 52,026
157 P A0.2 28,791 52,029
159 I L0.1 28,792 52,027
162 S D1.9 28,763 51,998
164 M L0.1 28,786 52,028
165 T L0.7 M0.1 28,787 52,021
167 I V0.6 28,788 52,020
184 M V52.5 I2.5 28,777 52,016
203 E K5.4 V0.4 A0.3 N0.1 28,736 51,864
205 L F0.1 28,738 51,841
208 H Y7.2 F0.3 28,725 51,820
210 L W17.7 Y0.1 R0.1 28,688 51,798
211 R D0.3 28,700 51,755
212 W M0.2 C0.1 L0.1 28,705 51,789
215 T Y26.3 F10.3 S2.1 I1.9 N1.0 C0.9 D0.8 V0.7 E0.2
G0.1 H0.1
28,657 51,505
218 D E5.6 28,653 51,454
219 K Q10.9 E6.1 N3.1 R2.7 D0.3 H0.3 W0.3 G0.1
S0.1
28,639 51,435
304 A G0.7 11,563 19,788
a Cons, consensus.
b Nonpolymorphic treatment-selected mutations (TSMs) in boldface were previously
reported as being associated with drug resistance (18). Lowercase “i” indicates an
insertion; lowercase “d” indicates a deletion.
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cause they nearly always occurred in combination with established
NRTI or NNRTI resistance mutations.
Of the 185 RT TSMs, 95 were selected by NRTIs and 64 were
selected by NNRTIs. For 26 RT TSMs, however, it was not possible
to determine whether the mutations were primarily selected by
NRTIs or NNRTIs because most of the individuals with these 26
TSMs received both NRTIs and NNRTIs.
Several mutations in the connection and RNase H domains of
RT have been shown to play an accessory role in reducing HIV-1
susceptibility in combination with thymidine analog mutations
(TAMs), most likely by slowing the activity of RNase H and
thereby allowing more time for TAM-mediated primer unblock-
ing (31). However, only 11 TSMs were identified beyond position
300, including the NRTI-selected mutation A304G, the NNRTI-
selected mutations Y318F, N348IT, and E404N, and the RTI-se-
lected mutations E302D, E312G, I341F, Q394S, E399G, and
Q547G. This is consistent with the much lower number of se-
quenced viruses extending beyond position 300 obtained from
NRTI- and/or NNRTI-experienced individuals.
We identified 30 nonpolymorphic IN TSMs, including 23 es-
tablished INSTI resistance mutations (H51Y, T66IAK, E92Q,
Q95K, F121Y, E138KA, G140SAC, Y143RCHSG, S147G,
Q148HRK, N155H, and S230R) and seven novel mutations not
previously associated with INSTI resistance. Four of the novel
mutations—E92A, E138T, Q148N, and N155D—were at posi-
tions also containing established INSTI resistance mutations.
Three other mutations—V79I, P142T, and D253Y—were at novel
positions. Eighty-two percent of the sequences containing one of
these three novel nonpolymorphic TSMs had one or more estab-
lished INSTI-associated DRMs.
Four well-characterized accessory INSTI-associated DRMs—
L74M, T97A, and G163R/K—were not identified because they
were polymorphic in one or more subtypes (32). G118R and
R263K, two other highly studied mutations (21, 33), were also not
TABLE 4 NNRTI nonpolymorphic treatment-selected mutations
Position Consa TSM(s)b
No. of individuals
RTI
treated
RTI
naive
94 I L0.6 28,810 52,041
98 A G5.7 28,802 52,042
100 L I3.6 28,796 51,999
101 K E6.6 P1.3 H1.1 N0.4 T0.3 A0.2 D0.1 28,794 52,039
102 K N0.4 G0.1 28,804 52,028
103 K N30.7 S1.6 T0.2 H0.1 28,805 52,032
105 S T0.2 28,808 52,045
106 V M4.0 A1.4 28,805 52,045
108 V I7.4 28,808 52,043
132 I L0.7 28,800 52,037
138 E Q1.0 K0.5 T0.1 28,798 52,024
139 T R0.8 28,798 52,037
178 I F0.2 28,781 52,001
179 V F0.2 L0.1 M0.1 28,774 52,010
181 Y C16.6 I0.7 V0.5 F0.2 G0.1 N0.1 28,780 52,016
188 Y L3.7 C0.8 H0.7 F0.4 28,758 52,014
190 G A12.7 S2.3 E0.4 Q0.3 C0.1 28,771 52,015
221 H Y6.1 C0.1 28,565 50,963
225 P H3.7 28,386 50,583
227 F L2.3 Y0.2 28,165 50,128
230 M L1.4 28,081 49,720
232 Y H0.3 27,827 49,437
234 L I0.2 27,760 49,216
238 K T1.9 N0.4 27,404 47,232
240 T K0.1 23,831 46,204
241 V M0.2 23,586 44,549
242 Q H0.9 L0.2 K0.1 23,529 43,984
318 Y F1.3 10,809 15,668
348 N I13.0 T0.8 6,367 5,528
404 E N1.3 1,207 3,663
a Cons, consensus.
b Nonpolymorphic treatment-selected mutations (TSMs) in boldface were previously
reported as being associated with drug resistance (18).
TABLE 5 Undifferentiated RTI nonpolymorphic treatment-selected
mutations
Position Consa TSM(s)b
No. of individuals
RTI
treated RTI naive
3 S C0.3 19,241 42,633
16 M V0.4 19,884 43,640
31 I L1.6 21,490 45,863
33 A V0.2 21,573 46,050
34 L I0.7 21,582 46,129
54 N I0.1 28,794 51,991
58 T N0.2 S0.2 28,795 51,994
109 L I0.8 M0.1 V0.1 28,808 52,043
202 I T0.1 28,742 51,873
223 K Q2.1 E1.7 T0.5 P0.1 28,537 50,880
228 L R5.4 N0.1 I0.1 K0.1 28,148 50,071
302 E D0.3 12,507 20,464
312 E G0.4 10,935 17,751
341 I F1.4 6,671 5,802
394 Q S0.8 6,108 4,874
399 E G1.2 5,882 4,830
547 Q R3.6 473 2,559
a Cons, consensus.
b Nonpolymorphic treatment-selected mutations (TSMs) in boldface were previously
reported as being associated with drug resistance (18).
TABLE 6 INSTI nonpolymorphic treatment-selected mutations
Position Consa TSM(s)b
No. of individuals
INSTI
treated
INSTI
naive
51 H Y0.5 1,019 6,609
66 T I1.3 A0.7 K0.4 1,019 6,619
79 V I2.5 1,020 6,625
92 E Q6.4 A0.4 1,020 6,628
95 Q K1.6 1,020 6,627
121 F Y0.4 1,020 6,631
138 E K5.9 A3.0 T0.7 1,020 6,631
140 G S25.2 A2.1 C0.7 1,020 6,631
142 P T0.6 1,020 6,631
143 Y R7.7 C5.4 H2.8 S0.6 G0.4 1,020 6,631
147 S G1.6 1,020 6,631
148 Q H22.6 R7.9 K1.0 N0.4 1,020 6,629
155 N H30.8 D0.5 1,020 6,629
230 S R3.6 1,018 6,608
253 D Y1.0 1,018 6,588
a Cons, consensus.
b Nonpolymorphic treatment-selected mutations (TSMs) in boldface were previously
reported as being associated with drug resistance (9).
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identified. G118R is extremely rare and was not present in a single
plasma virus sequence. R263K was significantly more common in
INSTI-treated than INSTI-naive sequences (6/1,016 [0.59%] ver-
sus 8/6558 [0.12%]), but this difference was not significant after
controlling for multiple comparisons.
Although practically all major drug resistance mutations are
TSMs, the converse may not always be true. For example, many
TSMs are accessory mutations that only arise in the presence of
other drug resistance mutations. Other TSMs such as the T215
revertant mutations T215S/C/E/D/I/V have been shown to arise
from drug resistance mutations (e.g., T215Y/F) when selective
drug pressure is removed (34).
APOBEC. We previously published an analysis of mutations
indicative of APOBEC-mediated RNA editing that encompassed
PR and the first 240 positions of RT (13). Our current analysis
identified two new mutations in PR and one new mutation in the
previously analyzed region of RT. Additionally, we identified 55
mutations between RT positions 241 and 560 and 71 mutations in
IN that are also likely to result from APOBEC-mediated RNA
editing. We then predicted that most sequences with two or more
of these mutations were likely to have undergone G-to-A hyper-
mutation.
Identification of sequences with G-to-A hypermutation is
important because the extent of hypermutation is usually in-
complete and may not be uniformly distributed (13, 35, 36)
and because several mutations known to emerge from selective
drug pressure can also arise from G-to-A hypermutation, in-
cluding D30N, M46I, and G73S in PR, D67N, E138K, M184I,
G190SE, and M230I in RT, and E138K, G118R, and G163R in
IN. As drug resistance testing in low- and middle-income
countries will increasingly be performed using dried blood
spots, which often contain proviral HIV-1 DNA (36–39), it will
become necessary to determine if a sequence has evidence of
G-to-A hypermutation to assess the clinical significance of the
above drug resistance mutations. For example, the isolated
presence of DRMs associated with G-to-A hypermutation
would need to be judged differently if they occurred in a se-
quence containing an excess of the APOBEC-indicating muta-
tions that we describe in this study.
Conclusions. This study of HIV-1 PR, RT, and IN variability
makes it possible to apportion amino acid variants into the fol-
lowing categories: (i) established variants that may or may not be
a nonpolymorphic TSM, (ii) APOBEC-associated mutations, and
(iii) very rare variants of questionable validity or replication po-
tential.
Determination of whether a particular sequence contains an
excess of APOBEC-associated mutations or of very rare amino
acid variants can be used to optimally determine the signifi-
cance of other mutations present in that sequence, particularly
when that sequence is generated using technologies associated
with greater sequencing artifacts, as occurs with the use of sam-
ples likely to be enriched for proviral DNA or with NGS deep
sequencing. As the number of sequences for IN and the 3= part
of RT was approximately 10-fold lower than those for PR and
the 5= part of RT and as subtype B was overly represented in our
data set, we will update our estimates of the prevalence of each
mutation at each position as additional sequence data are avail-
able.
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